Amgen Inc. stock underperforms Friday when compared to competitors
Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.
Agios Pharma (AGIO) Receives a Buy from RBC Capital
In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...
RBC Capital Keeps Their Buy Rating on aTyr Pharma (ATYR)
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...
FierceBiotech2d
Amgen ends Ideaya cancer combination trial after partner unveils rival molecule
While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...
Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript
Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...
$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
News Medical6d
Distinct myeloid-derived suppressor cell populations fuel aggressive brain tumor growth
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...